July 17, 2008

$65 Price Target on Abbott Laboratories

Zacks has an article out today that gives a $65 price target on Abbott Laboratories (ABT). From the article:

"ABT will deliver double-digit EPS growth through the end of 2012, driven by strong sales of the anti-inflammatory for rheumatoid arthritis and psoriasis, Humira, and the company's rapidly growing vascular business. Several new drug applications have recently been filed with the Food and Drug Administration (FDA), which should accelerate sales in the pharmaceutical business."

No comments: